Nutritional Supplementation in the Elderly With Weight Loss

NCT ID: NCT04350762

Last Updated: 2023-05-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

4 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-05

Study Completion Date

2020-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Many elderly experience weight loss and weakness with normal aging. Although there is extensive literature regarding nutritional advice for the elderly, there are few well- designed studies evaluating the effect of oral nutrition supplements in patients with weight loss and aging. The aim of this study is to examine the effect of dietary prescription with or without nutrition supplementation that includes soy protein, whey protein and fish oil in elderly patients who have suffered unintentional weight loss.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an 8-week, randomized, pilot study with elderly subjects (age 65 and older) with recent unintentional weight loss who will receive either two servings of supplement powder and fish oil or no dietary supplementation (N=10 for each group).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Supplement + Fish Oil

Participants will mix 5 scoops of powdered nutrition supplement with 8 oz of cold water (2x/day). The supplemental shake will be consumed on two separate occasions daily. Omega-3 fish oil supplement is in capsule form for intake once daily.

The NutraWell nutrition powder and OmegaRich fish oil supplement will be provided by and distributed from DoWell Laboratories (Irvine, CA - USA).

Group Type EXPERIMENTAL

Protein shake + Fish Oil

Intervention Type DIETARY_SUPPLEMENT

2 shakes of protein as well as 1 fish oil daily.

Control

No dietary supplements. Participants will continue current intake.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Protein shake + Fish Oil

2 shakes of protein as well as 1 fish oil daily.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female age 65 and older
* Non-smokers
* Weight loss \>3% body weight over 6-12 months
* BMI ≤ 25
* Living independently or in an assisted living facility

Exclusion Criteria

* Medical conditions that would lead to weight loss

* Active cancer undergoing treatment (chemotherapy, radiation therapy, or planned surgical intervention)
* CKD stage IV-V (eGFR \<30) based on medical records within the last 12 months
* Presence of dysphagia or odynophagia
* Actively taking blood thinner such as Warfarin
* Known history of cirrhosis with presence of ascites
* History of a surgical procedure for weight loss (e.g. gastroplasty, gastric bypass, gastrectomy or partial gastrectomy, lap-band)
* Any abnormal lab findings outside of normal limits as determined by the investigator
* Dietary conditions

* Diet restrictions including vegetarianism, veganism, soy-free diet,
* Fish and/or fish oil allergy or intolerance
* Milk allergy excluding lactose intolerance
* Follows a kosher diet
* Medications

* Use of appetite stimulants (including megestrol, dronabinol and cyproheptadine).
* Does not include medications used for depression (e.g. mirtazapine, paxil) if patient has been on a stable dose of this medication for at least 3 months prior to the start of this study
* If participant is already taking a fish oil supplement, he/she must be willing to either stop the supplement or take the supplement the investigators are using in the study depending on the randomization assignment
* Additional

* Patient has implantable device such as a pacemaker or ICD
* Unable to complete 6-minute walk test at baseline
* Hospitalization within the last 30 days
* Participation in a therapeutic research study within 30 days of baseline
* Living in a skilled nursing facility or long-term care facility
* Any other medical condition that principal investigator or co-investigators deem would preclude the patient from study participation
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of California, Los Angeles

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Zhaoping Li

Chief / Professor of Medicine

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Zhaoping Li

Role: PRINCIPAL_INVESTIGATOR

University of California, Los Angeles

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

UCLA Center for Human Nutrition, 1000 Veteran Ave.

Los Angeles, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

18-001995

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.